糖尿病性神経障害性疼痛治療剤の世界市場インサイト・予測(~2028年)

◆英語タイトル:Global Diabetic Neuropathic Pain Drug Market Insights and Forecast to 2028

QYResearchが発行した調査報告書(QY22MA00001)◆商品コード:QY22MA00001
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年3月
◆ページ数:111
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

新型コロナウイルス感染症のパンデミックにより、世界の糖尿病性神経障害性疼痛治療剤の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に糖尿病性神経障害性疼痛治療剤の世界市場のxxx%を占める「AZD-5213」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「診療所」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国の糖尿病性神経障害性疼痛治療剤の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの糖尿病性神経障害性疼痛治療剤市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの糖尿病性神経障害性疼痛治療剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

糖尿病性神経障害性疼痛治療剤のグローバル主要メーカーには、Astellas Pharma Inc.、AstraZeneca Plc、BioDelivery Sciences International, Inc.、Boehringer Ingelheim GmbH、Daiichi Sankyo Company, Limited、Dong-A Socio Group、Eli Lilly and Company、Glenmark Pharmaceuticals Ltd.、Hydra Biosciences, Inc.、Immune Pharmaceuticals Inc.、Laboratorios Del Dr. Esteve S.A.、Lohocla Research Corporation、Mertiva AB、Novaremed、Pharmaleads、RAPID Pharmaceuticals AG、Relmada Therapeutics, Inc.、Sphaera Pharma Pvt. Ltd.、Theravasc, Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

糖尿病性神経障害性疼痛治療剤市場は、種類と用途によって区分されます。世界の糖尿病性神経障害性疼痛治療剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
AZD-5213、塩酸クロニジン、塩酸デュロキセチンDR、E-52862、Filgrastim、GERPOOI、GRC-17536、その他

【用途別セグメント】
診療所、病院、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 糖尿病性神経障害性疼痛治療剤製品概要
- 種類別市場(AZD-5213、塩酸クロニジン、塩酸デュロキセチンDR、E-52862、Filgrastim、GERPOOI、GRC-17536、その他)
- 用途別市場(診療所、病院、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の糖尿病性神経障害性疼痛治療剤販売量予測2017-2028
- 世界の糖尿病性神経障害性疼痛治療剤売上予測2017-2028
- 糖尿病性神経障害性疼痛治療剤の地域別販売量
- 糖尿病性神経障害性疼痛治療剤の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別糖尿病性神経障害性疼痛治療剤販売量
- 主要メーカー別糖尿病性神経障害性疼痛治療剤売上
- 主要メーカー別糖尿病性神経障害性疼痛治療剤価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(AZD-5213、塩酸クロニジン、塩酸デュロキセチンDR、E-52862、Filgrastim、GERPOOI、GRC-17536、その他)
- 糖尿病性神経障害性疼痛治療剤の種類別販売量
- 糖尿病性神経障害性疼痛治療剤の種類別売上
- 糖尿病性神経障害性疼痛治療剤の種類別価格
・用途別市場規模(診療所、病院、その他)
- 糖尿病性神経障害性疼痛治療剤の用途別販売量
- 糖尿病性神経障害性疼痛治療剤の用途別売上
- 糖尿病性神経障害性疼痛治療剤の用途別価格
・北米市場
- 北米の糖尿病性神経障害性疼痛治療剤市場規模(種類別、用途別)
- 主要国別の糖尿病性神経障害性疼痛治療剤市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの糖尿病性神経障害性疼痛治療剤市場規模(種類別、用途別)
- 主要国別の糖尿病性神経障害性疼痛治療剤市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の糖尿病性神経障害性疼痛治療剤市場規模(種類別、用途別)
- 主要国別の糖尿病性神経障害性疼痛治療剤市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の糖尿病性神経障害性疼痛治療剤市場規模(種類別、用途別)
- 主要国別の糖尿病性神経障害性疼痛治療剤市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの糖尿病性神経障害性疼痛治療剤市場規模(種類別、用途別)
- 主要国別の糖尿病性神経障害性疼痛治療剤市場規模(トルコ、サウジアラビア)
・企業情報
Astellas Pharma Inc.、AstraZeneca Plc、BioDelivery Sciences International, Inc.、Boehringer Ingelheim GmbH、Daiichi Sankyo Company, Limited、Dong-A Socio Group、Eli Lilly and Company、Glenmark Pharmaceuticals Ltd.、Hydra Biosciences, Inc.、Immune Pharmaceuticals Inc.、Laboratorios Del Dr. Esteve S.A.、Lohocla Research Corporation、Mertiva AB、Novaremed、Pharmaleads、RAPID Pharmaceuticals AG、Relmada Therapeutics, Inc.、Sphaera Pharma Pvt. Ltd.、Theravasc, Inc.
・産業チェーン及び販売チャネル分析
- 糖尿病性神経障害性疼痛治療剤の産業チェーン分析
- 糖尿病性神経障害性疼痛治療剤の原材料
- 糖尿病性神経障害性疼痛治療剤の生産プロセス
- 糖尿病性神経障害性疼痛治療剤の販売及びマーケティング
- 糖尿病性神経障害性疼痛治療剤の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 糖尿病性神経障害性疼痛治療剤の産業動向
- 糖尿病性神経障害性疼痛治療剤のマーケットドライバー
- 糖尿病性神経障害性疼痛治療剤の課題
- 糖尿病性神経障害性疼痛治療剤の阻害要因
・主な調査結果

Market Analysis and Insights: Global Diabetic Neuropathic Pain Drug Market
Due to the COVID-19 pandemic, the global Diabetic Neuropathic Pain Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, AZD-5213 accounting for % of the Diabetic Neuropathic Pain Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Clinic segment is altered to an % CAGR throughout this forecast period.
China Diabetic Neuropathic Pain Drug market size is valued at US$ million in 2021, while the US and Europe Diabetic Neuropathic Pain Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Diabetic Neuropathic Pain Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Diabetic Neuropathic Pain Drug include Astellas Pharma Inc., AstraZeneca Plc, BioDelivery Sciences International, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Dong-A Socio Group, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd. and Hydra Biosciences, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Diabetic Neuropathic Pain Drug Scope and Segment
Diabetic Neuropathic Pain Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Diabetic Neuropathic Pain Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
AZD-5213
Clonidine Hydrochloride
Duloxetine Hydrochloride DR
E-52862
Filgrastim
GERPOOI
GRC-17536
Others
Segment by Application
Clinic
Hospital
Others
By Company
Astellas Pharma Inc.
AstraZeneca Plc
BioDelivery Sciences International, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Mertiva AB
Novaremed
Pharmaleads
RAPID Pharmaceuticals AG
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Theravasc, Inc.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

❖ レポートの目次 ❖

1 Study Coverage
1.1 Diabetic Neuropathic Pain Drug Product Introduction
1.2 Market by Type
1.2.1 Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 AZD-5213
1.2.3 Clonidine Hydrochloride
1.2.4 Duloxetine Hydrochloride DR
1.2.5 E-52862
1.2.6 Filgrastim
1.2.7 GERPOOI
1.2.8 GRC-17536
1.2.9 Others
1.3 Market by Application
1.3.1 Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Diabetic Neuropathic Pain Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Diabetic Neuropathic Pain Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Diabetic Neuropathic Pain Drug Sales by Region
2.4.1 Global Diabetic Neuropathic Pain Drug Sales by Region (2017-2022)
2.4.2 Global Sales Diabetic Neuropathic Pain Drug by Region (2023-2028)
2.5 Global Diabetic Neuropathic Pain Drug Revenue by Region
2.5.1 Global Diabetic Neuropathic Pain Drug Revenue by Region (2017-2022)
2.5.2 Global Diabetic Neuropathic Pain Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Diabetic Neuropathic Pain Drug Sales by Manufacturers
3.1.1 Global Top Diabetic Neuropathic Pain Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diabetic Neuropathic Pain Drug in 2021
3.2 Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers
3.2.1 Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Diabetic Neuropathic Pain Drug Revenue in 2021
3.3 Global Diabetic Neuropathic Pain Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Diabetic Neuropathic Pain Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Diabetic Neuropathic Pain Drug Sales by Type
4.1.1 Global Diabetic Neuropathic Pain Drug Historical Sales by Type (2017-2022)
4.1.2 Global Diabetic Neuropathic Pain Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
4.2 Global Diabetic Neuropathic Pain Drug Revenue by Type
4.2.1 Global Diabetic Neuropathic Pain Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Diabetic Neuropathic Pain Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
4.3 Global Diabetic Neuropathic Pain Drug Price by Type
4.3.1 Global Diabetic Neuropathic Pain Drug Price by Type (2017-2022)
4.3.2 Global Diabetic Neuropathic Pain Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Diabetic Neuropathic Pain Drug Sales by Application
5.1.1 Global Diabetic Neuropathic Pain Drug Historical Sales by Application (2017-2022)
5.1.2 Global Diabetic Neuropathic Pain Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
5.2 Global Diabetic Neuropathic Pain Drug Revenue by Application
5.2.1 Global Diabetic Neuropathic Pain Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Diabetic Neuropathic Pain Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
5.3 Global Diabetic Neuropathic Pain Drug Price by Application
5.3.1 Global Diabetic Neuropathic Pain Drug Price by Application (2017-2022)
5.3.2 Global Diabetic Neuropathic Pain Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Diabetic Neuropathic Pain Drug Market Size by Type
6.1.1 North America Diabetic Neuropathic Pain Drug Sales by Type (2017-2028)
6.1.2 North America Diabetic Neuropathic Pain Drug Revenue by Type (2017-2028)
6.2 North America Diabetic Neuropathic Pain Drug Market Size by Application
6.2.1 North America Diabetic Neuropathic Pain Drug Sales by Application (2017-2028)
6.2.2 North America Diabetic Neuropathic Pain Drug Revenue by Application (2017-2028)
6.3 North America Diabetic Neuropathic Pain Drug Market Size by Country
6.3.1 North America Diabetic Neuropathic Pain Drug Sales by Country (2017-2028)
6.3.2 North America Diabetic Neuropathic Pain Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Diabetic Neuropathic Pain Drug Market Size by Type
7.1.1 Europe Diabetic Neuropathic Pain Drug Sales by Type (2017-2028)
7.1.2 Europe Diabetic Neuropathic Pain Drug Revenue by Type (2017-2028)
7.2 Europe Diabetic Neuropathic Pain Drug Market Size by Application
7.2.1 Europe Diabetic Neuropathic Pain Drug Sales by Application (2017-2028)
7.2.2 Europe Diabetic Neuropathic Pain Drug Revenue by Application (2017-2028)
7.3 Europe Diabetic Neuropathic Pain Drug Market Size by Country
7.3.1 Europe Diabetic Neuropathic Pain Drug Sales by Country (2017-2028)
7.3.2 Europe Diabetic Neuropathic Pain Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Diabetic Neuropathic Pain Drug Market Size by Type
8.1.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Diabetic Neuropathic Pain Drug Market Size by Application
8.2.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Diabetic Neuropathic Pain Drug Market Size by Region
8.3.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Diabetic Neuropathic Pain Drug Market Size by Type
9.1.1 Latin America Diabetic Neuropathic Pain Drug Sales by Type (2017-2028)
9.1.2 Latin America Diabetic Neuropathic Pain Drug Revenue by Type (2017-2028)
9.2 Latin America Diabetic Neuropathic Pain Drug Market Size by Application
9.2.1 Latin America Diabetic Neuropathic Pain Drug Sales by Application (2017-2028)
9.2.2 Latin America Diabetic Neuropathic Pain Drug Revenue by Application (2017-2028)
9.3 Latin America Diabetic Neuropathic Pain Drug Market Size by Country
9.3.1 Latin America Diabetic Neuropathic Pain Drug Sales by Country (2017-2028)
9.3.2 Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Type
10.1.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Application
10.2.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Country
10.3.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Astellas Pharma Inc.
11.1.1 Astellas Pharma Inc. Corporation Information
11.1.2 Astellas Pharma Inc. Overview
11.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Astellas Pharma Inc. Recent Developments
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Corporation Information
11.2.2 AstraZeneca Plc Overview
11.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Plc Recent Developments
11.3 BioDelivery Sciences International, Inc.
11.3.1 BioDelivery Sciences International, Inc. Corporation Information
11.3.2 BioDelivery Sciences International, Inc. Overview
11.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 BioDelivery Sciences International, Inc. Recent Developments
11.4 Boehringer Ingelheim GmbH
11.4.1 Boehringer Ingelheim GmbH Corporation Information
11.4.2 Boehringer Ingelheim GmbH Overview
11.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Boehringer Ingelheim GmbH Recent Developments
11.5 Daiichi Sankyo Company, Limited
11.5.1 Daiichi Sankyo Company, Limited Corporation Information
11.5.2 Daiichi Sankyo Company, Limited Overview
11.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Daiichi Sankyo Company, Limited Recent Developments
11.6 Dong-A Socio Group
11.6.1 Dong-A Socio Group Corporation Information
11.6.2 Dong-A Socio Group Overview
11.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Dong-A Socio Group Recent Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Corporation Information
11.7.2 Eli Lilly and Company Overview
11.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Eli Lilly and Company Recent Developments
11.8 Glenmark Pharmaceuticals Ltd.
11.8.1 Glenmark Pharmaceuticals Ltd. Corporation Information
11.8.2 Glenmark Pharmaceuticals Ltd. Overview
11.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Glenmark Pharmaceuticals Ltd. Recent Developments
11.9 Hydra Biosciences, Inc.
11.9.1 Hydra Biosciences, Inc. Corporation Information
11.9.2 Hydra Biosciences, Inc. Overview
11.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Hydra Biosciences, Inc. Recent Developments
11.10 Immune Pharmaceuticals Inc.
11.10.1 Immune Pharmaceuticals Inc. Corporation Information
11.10.2 Immune Pharmaceuticals Inc. Overview
11.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Immune Pharmaceuticals Inc. Recent Developments
11.11 Laboratorios Del Dr. Esteve S.A.
11.11.1 Laboratorios Del Dr. Esteve S.A. Corporation Information
11.11.2 Laboratorios Del Dr. Esteve S.A. Overview
11.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
11.12 Lohocla Research Corporation
11.12.1 Lohocla Research Corporation Corporation Information
11.12.2 Lohocla Research Corporation Overview
11.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Lohocla Research Corporation Recent Developments
11.13 Mertiva AB
11.13.1 Mertiva AB Corporation Information
11.13.2 Mertiva AB Overview
11.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Mertiva AB Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Mertiva AB Recent Developments
11.14 Novaremed
11.14.1 Novaremed Corporation Information
11.14.2 Novaremed Overview
11.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Novaremed Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Novaremed Recent Developments
11.15 Pharmaleads
11.15.1 Pharmaleads Corporation Information
11.15.2 Pharmaleads Overview
11.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Pharmaleads Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Pharmaleads Recent Developments
11.16 RAPID Pharmaceuticals AG
11.16.1 RAPID Pharmaceuticals AG Corporation Information
11.16.2 RAPID Pharmaceuticals AG Overview
11.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 RAPID Pharmaceuticals AG Recent Developments
11.17 Relmada Therapeutics, Inc.
11.17.1 Relmada Therapeutics, Inc. Corporation Information
11.17.2 Relmada Therapeutics, Inc. Overview
11.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Relmada Therapeutics, Inc. Recent Developments
11.18 Sphaera Pharma Pvt. Ltd.
11.18.1 Sphaera Pharma Pvt. Ltd. Corporation Information
11.18.2 Sphaera Pharma Pvt. Ltd. Overview
11.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Sphaera Pharma Pvt. Ltd. Recent Developments
11.19 Theravasc, Inc.
11.19.1 Theravasc, Inc. Corporation Information
11.19.2 Theravasc, Inc. Overview
11.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Theravasc, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Diabetic Neuropathic Pain Drug Industry Chain Analysis
12.2 Diabetic Neuropathic Pain Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diabetic Neuropathic Pain Drug Production Mode & Process
12.4 Diabetic Neuropathic Pain Drug Sales and Marketing
12.4.1 Diabetic Neuropathic Pain Drug Sales Channels
12.4.2 Diabetic Neuropathic Pain Drug Distributors
12.5 Diabetic Neuropathic Pain Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Diabetic Neuropathic Pain Drug Industry Trends
13.2 Diabetic Neuropathic Pain Drug Market Drivers
13.3 Diabetic Neuropathic Pain Drug Market Challenges
13.4 Diabetic Neuropathic Pain Drug Market Restraints
14 Key Findings in The Global Diabetic Neuropathic Pain Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of AZD-5213
Table 3. Major Manufacturers of Clonidine Hydrochloride
Table 4. Major Manufacturers of Duloxetine Hydrochloride DR
Table 5. Major Manufacturers of E-52862
Table 6. Major Manufacturers of Filgrastim
Table 7. Major Manufacturers of GERPOOI
Table 8. Major Manufacturers of GRC-17536
Table 9. Major Manufacturers of Others
Table 10. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 11. Global Diabetic Neuropathic Pain Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 12. Global Diabetic Neuropathic Pain Drug Sales by Region (2017-2022) & (K Pcs)
Table 13. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2017-2022)
Table 14. Global Diabetic Neuropathic Pain Drug Sales by Region (2023-2028) & (K Pcs)
Table 15. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2023-2028)
Table 16. Global Diabetic Neuropathic Pain Drug Revenue by Region (2017-2022) & (US$ Million)
Table 17. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2017-2022)
Table 18. Global Diabetic Neuropathic Pain Drug Revenue by Region (2023-2028) & (US$ Million)
Table 19. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2023-2028)
Table 20. Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 21. Global Diabetic Neuropathic Pain Drug Sales Share by Manufacturers (2017-2022)
Table 22. Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2017-2022)
Table 24. Diabetic Neuropathic Pain Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 25. Global Diabetic Neuropathic Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2021)
Table 27. Diabetic Neuropathic Pain Drug Manufacturing Base Distribution and Headquarters
Table 28. Manufacturers Diabetic Neuropathic Pain Drug Product Offered
Table 29. Date of Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Diabetic Neuropathic Pain Drug Sales by Type (2017-2022) & (K Pcs)
Table 32. Global Diabetic Neuropathic Pain Drug Sales by Type (2023-2028) & (K Pcs)
Table 33. Global Diabetic Neuropathic Pain Drug Sales Share by Type (2017-2022)
Table 34. Global Diabetic Neuropathic Pain Drug Sales Share by Type (2023-2028)
Table 35. Global Diabetic Neuropathic Pain Drug Revenue by Type (2017-2022) & (US$ Million)
Table 36. Global Diabetic Neuropathic Pain Drug Revenue by Type (2023-2028) & (US$ Million)
Table 37. Global Diabetic Neuropathic Pain Drug Revenue Share by Type (2017-2022)
Table 38. Global Diabetic Neuropathic Pain Drug Revenue Share by Type (2023-2028)
Table 39. Diabetic Neuropathic Pain Drug Price by Type (2017-2022) & (USD/Pcs)
Table 40. Global Diabetic Neuropathic Pain Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 41. Global Diabetic Neuropathic Pain Drug Sales by Application (2017-2022) & (K Pcs)
Table 42. Global Diabetic Neuropathic Pain Drug Sales by Application (2023-2028) & (K Pcs)
Table 43. Global Diabetic Neuropathic Pain Drug Sales Share by Application (2017-2022)
Table 44. Global Diabetic Neuropathic Pain Drug Sales Share by Application (2023-2028)
Table 45. Global Diabetic Neuropathic Pain Drug Revenue by Application (2017-2022) & (US$ Million)
Table 46. Global Diabetic Neuropathic Pain Drug Revenue by Application (2023-2028) & (US$ Million)
Table 47. Global Diabetic Neuropathic Pain Drug Revenue Share by Application (2017-2022)
Table 48. Global Diabetic Neuropathic Pain Drug Revenue Share by Application (2023-2028)
Table 49. Diabetic Neuropathic Pain Drug Price by Application (2017-2022) & (USD/Pcs)
Table 50. Global Diabetic Neuropathic Pain Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 51. North America Diabetic Neuropathic Pain Drug Sales by Type (2017-2022) & (K Pcs)
Table 52. North America Diabetic Neuropathic Pain Drug Sales by Type (2023-2028) & (K Pcs)
Table 53. North America Diabetic Neuropathic Pain Drug Revenue by Type (2017-2022) & (US$ Million)
Table 54. North America Diabetic Neuropathic Pain Drug Revenue by Type (2023-2028) & (US$ Million)
Table 55. North America Diabetic Neuropathic Pain Drug Sales by Application (2017-2022) & (K Pcs)
Table 56. North America Diabetic Neuropathic Pain Drug Sales by Application (2023-2028) & (K Pcs)
Table 57. North America Diabetic Neuropathic Pain Drug Revenue by Application (2017-2022) & (US$ Million)
Table 58. North America Diabetic Neuropathic Pain Drug Revenue by Application (2023-2028) & (US$ Million)
Table 59. North America Diabetic Neuropathic Pain Drug Sales by Country (2017-2022) & (K Pcs)
Table 60. North America Diabetic Neuropathic Pain Drug Sales by Country (2023-2028) & (K Pcs)
Table 61. North America Diabetic Neuropathic Pain Drug Revenue by Country (2017-2022) & (US$ Million)
Table 62. North America Diabetic Neuropathic Pain Drug Revenue by Country (2023-2028) & (US$ Million)
Table 63. Europe Diabetic Neuropathic Pain Drug Sales by Type (2017-2022) & (K Pcs)
Table 64. Europe Diabetic Neuropathic Pain Drug Sales by Type (2023-2028) & (K Pcs)
Table 65. Europe Diabetic Neuropathic Pain Drug Revenue by Type (2017-2022) & (US$ Million)
Table 66. Europe Diabetic Neuropathic Pain Drug Revenue by Type (2023-2028) & (US$ Million)
Table 67. Europe Diabetic Neuropathic Pain Drug Sales by Application (2017-2022) & (K Pcs)
Table 68. Europe Diabetic Neuropathic Pain Drug Sales by Application (2023-2028) & (K Pcs)
Table 69. Europe Diabetic Neuropathic Pain Drug Revenue by Application (2017-2022) & (US$ Million)
Table 70. Europe Diabetic Neuropathic Pain Drug Revenue by Application (2023-2028) & (US$ Million)
Table 71. Europe Diabetic Neuropathic Pain Drug Sales by Country (2017-2022) & (K Pcs)
Table 72. Europe Diabetic Neuropathic Pain Drug Sales by Country (2023-2028) & (K Pcs)
Table 73. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2017-2022) & (US$ Million)
Table 74. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2023-2028) & (US$ Million)
Table 75. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Type (2017-2022) & (K Pcs)
Table 76. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Type (2023-2028) & (K Pcs)
Table 77. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Type (2017-2022) & (US$ Million)
Table 78. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Type (2023-2028) & (US$ Million)
Table 79. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Application (2017-2022) & (K Pcs)
Table 80. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Application (2023-2028) & (K Pcs)
Table 81. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Application (2017-2022) & (US$ Million)
Table 82. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Application (2023-2028) & (US$ Million)
Table 83. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2017-2022) & (K Pcs)
Table 84. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2023-2028) & (K Pcs)
Table 85. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2017-2022) & (US$ Million)
Table 86. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2023-2028) & (US$ Million)
Table 87. Latin America Diabetic Neuropathic Pain Drug Sales by Type (2017-2022) & (K Pcs)
Table 88. Latin America Diabetic Neuropathic Pain Drug Sales by Type (2023-2028) & (K Pcs)
Table 89. Latin America Diabetic Neuropathic Pain Drug Revenue by Type (2017-2022) & (US$ Million)
Table 90. Latin America Diabetic Neuropathic Pain Drug Revenue by Type (2023-2028) & (US$ Million)
Table 91. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2017-2022) & (K Pcs)
Table 92. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2023-2028) & (K Pcs)
Table 93. Latin America Diabetic Neuropathic Pain Drug Revenue by Application (2017-2022) & (US$ Million)
Table 94. Latin America Diabetic Neuropathic Pain Drug Revenue by Application (2023-2028) & (US$ Million)
Table 95. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2017-2022) & (K Pcs)
Table 96. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2023-2028) & (K Pcs)
Table 97. Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2017-2022) & (US$ Million)
Table 98. Latin America Diabetic Neuropathic Pain Drug Revenue by Country (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2017-2022) & (K Pcs)
Table 100. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2023-2028) & (K Pcs)
Table 101. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Type (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Type (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2017-2022) & (K Pcs)
Table 104. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2023-2028) & (K Pcs)
Table 105. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Application (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Application (2023-2028) & (US$ Million)
Table 107. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2017-2022) & (K Pcs)
Table 108. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2023-2028) & (K Pcs)
Table 109. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country (2017-2022) & (US$ Million)
Table 110. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country (2023-2028) & (US$ Million)
Table 111. Astellas Pharma Inc. Corporation Information
Table 112. Astellas Pharma Inc. Description and Major Businesses
Table 113. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 114. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Astellas Pharma Inc. Recent Developments
Table 116. AstraZeneca Plc Corporation Information
Table 117. AstraZeneca Plc Description and Major Businesses
Table 118. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 119. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. AstraZeneca Plc Recent Developments
Table 121. BioDelivery Sciences International, Inc. Corporation Information
Table 122. BioDelivery Sciences International, Inc. Description and Major Businesses
Table 123. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 124. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. BioDelivery Sciences International, Inc. Recent Developments
Table 126. Boehringer Ingelheim GmbH Corporation Information
Table 127. Boehringer Ingelheim GmbH Description and Major Businesses
Table 128. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 129. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Boehringer Ingelheim GmbH Recent Developments
Table 131. Daiichi Sankyo Company, Limited Corporation Information
Table 132. Daiichi Sankyo Company, Limited Description and Major Businesses
Table 133. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 134. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Daiichi Sankyo Company, Limited Recent Developments
Table 136. Dong-A Socio Group Corporation Information
Table 137. Dong-A Socio Group Description and Major Businesses
Table 138. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 139. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Dong-A Socio Group Recent Developments
Table 141. Eli Lilly and Company Corporation Information
Table 142. Eli Lilly and Company Description and Major Businesses
Table 143. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 144. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Eli Lilly and Company Recent Developments
Table 146. Glenmark Pharmaceuticals Ltd. Corporation Information
Table 147. Glenmark Pharmaceuticals Ltd. Description and Major Businesses
Table 148. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 149. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Glenmark Pharmaceuticals Ltd. Recent Developments
Table 151. Hydra Biosciences, Inc. Corporation Information
Table 152. Hydra Biosciences, Inc. Description and Major Businesses
Table 153. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 154. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Hydra Biosciences, Inc. Recent Developments
Table 156. Immune Pharmaceuticals Inc. Corporation Information
Table 157. Immune Pharmaceuticals Inc. Description and Major Businesses
Table 158. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 159. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Immune Pharmaceuticals Inc. Recent Developments
Table 161. Laboratorios Del Dr. Esteve S.A. Corporation Information
Table 162. Laboratorios Del Dr. Esteve S.A. Description and Major Businesses
Table 163. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 164. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Laboratorios Del Dr. Esteve S.A. Recent Developments
Table 166. Lohocla Research Corporation Corporation Information
Table 167. Lohocla Research Corporation Description and Major Businesses
Table 168. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 169. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Lohocla Research Corporation Recent Developments
Table 171. Mertiva AB Corporation Information
Table 172. Mertiva AB Description and Major Businesses
Table 173. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 174. Mertiva AB Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Mertiva AB Recent Developments
Table 176. Novaremed Corporation Information
Table 177. Novaremed Description and Major Businesses
Table 178. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 179. Novaremed Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. Novaremed Recent Developments
Table 181. Pharmaleads Corporation Information
Table 182. Pharmaleads Description and Major Businesses
Table 183. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 184. Pharmaleads Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. Pharmaleads Recent Developments
Table 186. RAPID Pharmaceuticals AG Corporation Information
Table 187. RAPID Pharmaceuticals AG Description and Major Businesses
Table 188. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 189. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. RAPID Pharmaceuticals AG Recent Developments
Table 191. Relmada Therapeutics, Inc. Corporation Information
Table 192. Relmada Therapeutics, Inc. Description and Major Businesses
Table 193. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 194. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 195. Relmada Therapeutics, Inc. Recent Developments
Table 196. Sphaera Pharma Pvt. Ltd. Corporation Information
Table 197. Sphaera Pharma Pvt. Ltd. Description and Major Businesses
Table 198. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 199. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 200. Sphaera Pharma Pvt. Ltd. Recent Developments
Table 201. Theravasc, Inc. Corporation Information
Table 202. Theravasc, Inc. Description and Major Businesses
Table 203. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 204. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 205. Theravasc, Inc. Recent Developments
Table 206. Key Raw Materials Lists
Table 207. Raw Materials Key Suppliers Lists
Table 208. Diabetic Neuropathic Pain Drug Distributors List
Table 209. Diabetic Neuropathic Pain Drug Customers List
Table 210. Diabetic Neuropathic Pain Drug Market Trends
Table 211. Diabetic Neuropathic Pain Drug Market Drivers
Table 212. Diabetic Neuropathic Pain Drug Market Challenges
Table 213. Diabetic Neuropathic Pain Drug Market Restraints
Table 214. Research Programs/Design for This Report
Table 215. Key Data Information from Secondary Sources
Table 216. Key Data Information from Primary Sources
List of Figures
Figure 1. Diabetic Neuropathic Pain Drug Product Picture
Figure 3. Global Diabetic Neuropathic Pain Drug Market Share by Type in 2021 & 2028
Figure 3. AZD-5213 Product Picture
Figure 4. Clonidine Hydrochloride Product Picture
Figure 5. Duloxetine Hydrochloride DR Product Picture
Figure 6. E-52862 Product Picture
Figure 7. Filgrastim Product Picture
Figure 8. GERPOOI Product Picture
Figure 9. GRC-17536 Product Picture
Figure 10. Others Product Picture
Figure 11. Global Diabetic Neuropathic Pain Drug Market Share by Application in 2021 & 2028
Figure 12. Clinic
Figure 13. Hospital
Figure 14. Others
Figure 15. Diabetic Neuropathic Pain Drug Report Years Considered
Figure 16. Global Diabetic Neuropathic Pain Drug Sales 2017-2028 (K Pcs)
Figure 17. Global Diabetic Neuropathic Pain Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Diabetic Neuropathic Pain Drug Revenue 2017-2028 (US$ Million)
Figure 19. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 20. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2017-2022)
Figure 21. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2023-2028)
Figure 22. North America Diabetic Neuropathic Pain Drug Sales YoY (2017-2028) & (K Pcs)
Figure 23. North America Diabetic Neuropathic Pain Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Europe Diabetic Neuropathic Pain Drug Sales YoY (2017-2028) & (K Pcs)
Figure 25. Europe Diabetic Neuropathic Pain Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Asia-Pacific Diabetic Neuropathic Pain Drug Sales YoY (2017-2028) & (K Pcs)
Figure 27. Asia-Pacific Diabetic Neuropathic Pain Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Latin America Diabetic Neuropathic Pain Drug Sales YoY (2017-2028) & (K Pcs)
Figure 29. Latin America Diabetic Neuropathic Pain Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 30. Middle East & Africa Diabetic Neuropathic Pain Drug Sales YoY (2017-2028) & (K Pcs)
Figure 31. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 32. The Diabetic Neuropathic Pain Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 33. The Top 5 and 10 Largest Manufacturers of Diabetic Neuropathic Pain Drug in the World: Market Share by Diabetic Neuropathic Pain Drug Revenue in 2021
Figure 34. Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 35. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
Figure 36. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
Figure 37. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
Figure 38. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
Figure 39. North America Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
Figure 40. North America Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
Figure 41. North America Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
Figure 42. North America Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
Figure 43. North America Diabetic Neuropathic Pain Drug Sales Share by Country (2017-2028)
Figure 44. North America Diabetic Neuropathic Pain Drug Revenue Share by Country (2017-2028)
Figure 45. U.S. Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 46. Canada Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 47. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
Figure 48. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
Figure 49. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
Figure 50. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
Figure 51. Europe Diabetic Neuropathic Pain Drug Sales Share by Country (2017-2028)
Figure 52. Europe Diabetic Neuropathic Pain Drug Revenue Share by Country (2017-2028)
Figure 53. Germany Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 54. France Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 55. U.K. Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 56. Italy Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 57. Russia Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 58. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
Figure 59. Asia Pacific Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
Figure 60. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
Figure 61. Asia Pacific Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
Figure 62. Asia Pacific Diabetic Neuropathic Pain Drug Sales Share by Region (2017-2028)
Figure 63. Asia Pacific Diabetic Neuropathic Pain Drug Revenue Share by Region (2017-2028)
Figure 64. China Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 65. Japan Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 66. South Korea Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 67. India Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Australia Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Taiwan Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Indonesia Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 71. Thailand Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 72. Malaysia Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 73. Philippines Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 74. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
Figure 75. Latin America Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
Figure 76. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
Figure 77. Latin America Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
Figure 78. Latin America Diabetic Neuropathic Pain Drug Sales Share by Country (2017-2028)
Figure 79. Latin America Diabetic Neuropathic Pain Drug Revenue Share by Country (2017-2028)
Figure 80. Mexico Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 81. Brazil Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 82. Argentina Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 83. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Type (2017-2028)
Figure 84. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2017-2028)
Figure 85. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Application (2017-2028)
Figure 86. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2017-2028)
Figure 87. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Share by Country (2017-2028)
Figure 88. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Share by Country (2017-2028)
Figure 89. Turkey Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 90. Saudi Arabia Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 91. U.A.E Diabetic Neuropathic Pain Drug Revenue (2017-2028) & (US$ Million)
Figure 92. Diabetic Neuropathic Pain Drug Value Chain
Figure 93. Diabetic Neuropathic Pain Drug Production Process
Figure 94. Channels of Distribution
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 糖尿病性神経障害性疼痛治療剤の世界市場インサイト・予測(~2028年)(Global Diabetic Neuropathic Pain Drug Market Insights and Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆